首页> 外文期刊>癌と化学療法 >A patient with pancreatic cancer and multiple liver metastases after total pancreatectomy who showed a partial response to combination chemotherapy with gemcitabine and UFT
【24h】

A patient with pancreatic cancer and multiple liver metastases after total pancreatectomy who showed a partial response to combination chemotherapy with gemcitabine and UFT

机译:胰腺癌全胰腺切除术后多发肝转移的胰腺癌​​患者对吉西他滨联合UFT联合化疗表现出部分反应

获取原文
获取原文并翻译 | 示例
           

摘要

A 69-year-old man underwent a complete pancreatectomy in March 2002 because of cancer of the body of the pancreas. Two months after surgery, the patient had multiple metastases to the liver, abdominal recurrence, and an elevated cancer antigen (CA) 19-9 level. Combination chemotherapy with gemcitabine and UFT was administered on an outpatient basis. Chemotherapy consisted of biweekly gemcitabine (1,000 mg/m(2)) and daily UFT (300 mg). After 3 months of treatment, a computed tomographic scan of the liver showed marked shrinkage of metastatic lesions, accompanied by a decrease in the CA19-9 level. The patient spent most of his time at home and worked as usual; his quality of life was maintained. The only adverse event was transient leukopenia (grade 2). He died of peritoneal dissemination in August 2003 (15 months after recurrence). Our experience suggests that combination chemotherapy with gemcitabine and UFT may promote tumor dormancy and relieve symptoms in patients with liver metastasis after surgeryfor pancreatic cancer or with recurrence of metastasis.
机译:2002年3月,一名69岁的男子因胰腺癌而接受了完全胰腺切除术。手术后两个月,患者肝有多个转移灶,腹部复发,癌抗原(CA)19-9水平升高。门诊患者联合吉西他滨和UFT联合化疗。化学疗法包括每两周一次吉西他滨(1,000 mg / m(2))和每日UFT(300 mg)。治疗3个月后,肝脏X线断层扫描显示转移灶明显缩小,同时CA19-9水平降低。患者大部分时间都在家中照常工作。他的生活质量得到了维持。唯一的不良事件是短暂性白细胞减少症(2级)。他于2003年8月(复发15个月)死于腹膜扩散。我们的经验表明,吉西他滨联合UFT联合化疗可促进胰腺癌术后或转移复发的肝转移患者的肿瘤休眠和缓解症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号